Weight Loss

With a lack of well-defined guidelines, many primary care providers in the United Kingdom provided generic weight-loss advice to patients with obesity, a recent study found.

It is more appropriate to use BMI as the determinant for metabolic and bariatric surgery in treatment of type 2 diabetes.

During the past 20 years, Endocrine Today has reported on advancements in bariatric and metabolic surgery, including the evolution of the procedure and growth of high-quality clinical trial data documenting efficacy and safety.

Among adults with obesity, bariatric surgery conferred greater weight and BMI reductions than GLP-1 receptor agonist therapy, but effects on HbA1c were similar between the two modalities, researchers reported.

Primary care provider referral to an automated weight-loss program resulted in significantly increased weight loss at 6 and 12 months vs. usual care, according to study findings published in Obesity.

Time-restricted eating interventions, especially those with an eating window of 8 hours or longer, are not associated with weight loss of 5% or greater for most adults with obesity, according to a speaker.

A novel bispecific GIP receptor antagonist and GLP-1 receptor agonist induced weight loss of up to 14.5% in adults with obesity with no safety concerns, according to data from a phase 1 trial.

Adults with an elevated level of pancreatic fat have higher risk for developing incident diabetes, but weight loss may be able to lower diabetes risk by reducing fat levels and increasing pancreatic volume, according to a presenter.

Adults partaking in time-restricted eating have greater decreases in body weight, fat mass, fasting blood glucose and other cardiometabolic markers compared with controls, according to findings from a systematic review and meta-analysis.

It has long been said that the best way to treat obesity is to eat a healthy, reduced-calorie diet and exercise regularly.